The FDA has launched a Class II nationwide recall of specific lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. The tablets are subpotent and may cause temporary health effects. Patients are urged to consult healthcare providers before making any changes.
Key Takeaways
- FDA recalls specific lots of levothyroxine tablets.
- Recall classified as Class II – may cause temporary health effects.
- Patients should consult pharmacists before stopping medication.
Recall Overview
The Food and Drug Administration (FDA) has announced a nationwide recall of certain lot numbers of levothyroxine sodium tablets manufactured by Major Pharmaceuticals. Levothyroxine is a widely prescribed treatment for hypothyroidism and goiter.
Identifying Affected Lots
Recalled tablets are packaged in 10‑count blister packs, identified by lot numbers and expiration dates such as 25 µg (Lot N02212, Exp 07/2026) and 150 µg (Lot N02167, Exp 07/2026). A complete list is provided in the original notice.
What to Do If You Have the Medication
If your product matches any of the listed lot numbers, contact your doctor or pharmacist immediately. Do not discontinue the medication without professional guidance, as abrupt cessation can lead to adverse effects.
Why This Matters
BozokMedia analysis shows levothyroxine is the most prescribed thyroid medication in the United States; this recall could affect millions and place additional strain on the healthcare system.
"Subpotent tablets can destabilize patients' thyroid levels, making a swift recall essential," said Dr. Sarah Patel, endocrine specialist.
Frequently Asked Questions
Q1: Can I switch to a different strength without seeing my doctor?
A: No. Any change should be made under a physician’s prescription.
Q2: If my bottle isn’t listed, am I safe?
A: If your lot number isn’t on the recall list, your medication is considered safe, but continue routine monitoring.
